Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Allergic Rhinitis

In brief

This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis

Key facts

Study ID

NCT00929968

Run by

Novartis Pharmaceuticals

People needed

35

Starts

2009-06-01

Last updated by the study team

2020-12-19

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male and female subjects between ages of 18 to 60 in good health
• History of atopy for at least 2 years and positive skin prick test to ragweed allergen

You may not qualify if…

• History of asthma treated with corticosteroids
• Smokers with a smoking history of > 10 pack/years or smoking in the past year
• History of chronic obstructive pulmonary disease
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States
• Novartis Investigative Site — Ottawa, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.